

## CURRICULUM VITAE

Position: Associate Professor  
Department of Medicine, Division of Infectious Disease

Addresses: The University of Vermont Medical Center  
Department of Medicine, Infectious Disease  
111 Colchester Avenue, Smith 248  
Burlington, VT 05401

The University of Vermont  
The Robert Larner, M.D. College of Medicine  
89 Beaumont Avenue  
Burlington, VT 05405

Voice: (802) 847-3819  
email: [Kristen.pierce@uvmhealth.org](mailto:Kristen.pierce@uvmhealth.org)

## EDUCATION

2006-2008	Fletcher Allen Health Care and the University of Vermont	Fellowship: Infectious Disease
2003-2006	Fletcher Allen Health Care and the University of Vermont	Residency: Internal Medicine
1998-2003	University of Vermont, College of Medicine	M. D.
1988-1993	University of Colorado, Boulder	B. A. in Humanities and Art History

## LICENSES, CERTIFICATION

2009-present	Board Certified, Infectious Disease
2007-present	Board Certified, Internal Medicine Recertified October 2017
2003-Present	VT Medical License

### **FACULTY POSITIONS HELD**

2018-Present	University of Vermont, COM	Adjunct Associate Professor	Microbiology and Molecular Genetics
2014-Present	University of Vermont, COM	Associate Professor	Medicine
2008-2014	University of Vermont, COM	Assistant Professor	Medicine
2006-2008	University of Vermont, COM	Clinical Instructor	Medicine

### **OTHER POSITIONS AND MAJOR ADMINISTRATIVE POSITIONS HELD**

2017 -Present	Department of Medicine Reappointment Committee	Chair
2016	Vaccine Testing Center, UVM	Interim Director
2013- present	Infectious Disease Fellowship Training Program	Director
2011-2013	Infectious Disease Fellowship Training Program	Associate Director

### **HONORS AND AWARDS**

2012	2012 Early Career Women Faculty Professional Development Seminar July 7-10, 2012 Potomac, MD
2017	Early Achievement Award, UVM Medical Alumni Association

### **QUALITY IMPROVEMENT AND PATIENT SAFETY ACTIVITIES**

2017-2018	ID Division Quality Project: “Meningococcal Vaccine in HIV Patients”
2018- Present	ID Division Quality Project: “Inpatient Screening for Hepatitis C with link Outpatient Care at Discharge”

## **KEYWORDS/AREAS OF INTEREST**

My clinical work encompasses both inpatient and outpatient clinical Infectious Diseases. The inpatient work ranges from infections in immunocompromised hosts to post-operative infections. Our inpatient consult service is extremely busy, ranging from 25-60 inpatients at any given time. The majority of my outpatient time is spent seeing patients living with HIV, Tuberculosis, travel-related infections and general infectious diseases.

My research work focuses mainly on vaccine research. I am a lead clinical investigator and site Principal Investigator at the Vaccine Testing Center (VTC) here at UVM. My focus is primarily on flavivirus vaccine research. In conjunction with our collaborators the National Institutes of Health (NIH) and Johns Hopkins Bloomberg School of Public Health, we have been examining the safety, efficacy and immunogenicity of a Live-attenuated Dengue Vaccine, a West Nile Virus Vaccine and a Zika vaccine. Since 2009, I have led the clinical team and in the last few years have transitioned to be the site Principal Investigator for these studies. In this role, I am responsible for protocol development, study buildup, volunteer safety as well as reporting and data review. I work closely with our collaborators at JHU and the NIH to determine what next steps/studies will need to be developed based on the results of each individual trial. In addition, our work at UVM has expanded to encompass Controlled Human Infection Models (CHIM) for many of these same pathogens. This a unique area of vaccine research requiring a thorough understanding of the characteristics of the pathogen, the disease state and the complex interplay between human host and pathogen. In my role as the site principal investigator at the Vaccine Testing Center here at UVM, I have been integral in developing our CHIM at UVM, and have been the site PI doing these studies for several years now I have been involved in some of the early enteric challenge models, but serve primarily now to oversee and develop the flavivirus CHIM here at UVM as well as serve as site PI for the flavivirus vaccine studies.

## **SUMMARY OF PROFESSIONAL ACTIVITIES- OVERALL**

I was hired in 2008 as an Assistant Professor and was promoted in 2014 to Associate Professor. My current breakdown has been 27% of effort for research, 41% clinical effort, 17% for teaching, and 15% for administrative effort (Fellowship (10%) and Reappointment and Promotions (5%). I am board-certified in both Internal Medicine and Infectious Diseases. My clinical practice consists of inpatient consultative ID and outpatient HIV, STI, travel and general infectious disease. I am currently engaged in a variety of service activities for the College of Medicine, the Department of Medicine, our ID Division and UVMHC at large. In addition, I have had the privileged to provide mentorship to a variety of individuals including medical students, residents, fellows and physician colleagues. I provide high quality instruction to medical students, residents and fellows both at the bedside and formal didactic lectures. I have lectured regionally on a variety of topics and internationally regarding Flavivirus vaccine development, and have published articles in peer reviewed publications as well as book chapters.

### **Summary of Service:**

I divide my clinical time between the inpatient ID consult service and the outpatient clinic here at UVM. Our inpatient service consists of three separate services- teaching, non-teaching and ICU. During the time on the teaching rotation I will see patients with the fellows, students and residents. Each of these 3 clinical services is quite busy with an overall heavy consult load. I spend a range of 18-20 weeks per year on the inpatient service While in the outpatient clinic I

see patients living with HIV, Hepatitis C, TB and general ID issues. I currently serve on several committees at the UVM level including the Infectious Disease Practice Committee and the Infection Prevention Committee as well as being an active member of the microbiology search committee. At the Departmental level, I am a member of the Faculty Development Committee, and I am the Chair of the Reappointment Sub-Committee. This year I have been asked to Chair the DOM Reappointment Committees and in this role I will oversee all three faculty committees (TenureTrack, Clinical Scholars Pathway and Volunteer Pathway) evaluating faculty for reappointment and promotion. In this role I will report directly to the Vice Chair for Academic Affairs; this work will support 5% of my effort starting in the Summer of 2019. I am also involved with teaching the medical residents and participate in the Resident Selection Committee doing residency interviews. At the division level, I participate in our divisions joint quality projects, have served on each ID recruitment committee. I am the Fellowship director for the ID Training Program and in this role, I am responsible for all the day to day administrative duties of our two ID fellows. I also serve to chair our Clinical Competency Committee and our Program Evaluation Committee for the ID Fellowship I am responsible for developing our ID conference lecture schedule each year which is attended by all ID faculty, fellows, as well as participants from the VT Department of Health and the Microbiology Department. This year I worked with our clinic supervisor and the Office of Clinical Research to develop a program which allows the ID attendings to use the services of the Office of Clinical Trials Research (OCTR) in obtaining expanded access medications. This is a process that can take hours and involves a significant amount of time, attempting to obtain drugs for patients. Our system now allows the ID physicians to work collaboratively with the OCTR saving time on the physician end and utilizing the expertise of the OCTR. At the University level, I am an active member of the IRB and was asked to be a member of the Complex System Search Committee 2 years ago. Nationally, I am actively engaged in society memberships (IDSA and ASTMH) and have served as a reviewer for *Critical Care Medicine* as well as *The American Society of Tropical Medicine and Hygiene*. At the National level, I have been asked to serve on the American Council of Immunization Practices, Flavivirus Working Group. This a group at the CDC which functions to review data and clinical studies on developing flavivirus vaccines and to provide advice on how best to roll out these vaccines in the US. On an International level I have been asked to serve on the Candidate Vaccine Advisory Committee (CVAC) Steering Group on preparedness for Flavivirus Vaccines, Indian/US working group (Indo-VAP). This represents an international group of researchers and clinical trial specialists working with the Indian Government in an advisory role as they begin their dengue vaccine studies; we met in New Delhi in January of this year.

**Summary of Teaching:**

I currently enjoying teaching and mentoring a wide range of learners including undergraduates, LCOM students, UVM residents as well as Fellows. I provide daily informal teaching in the clinical setting to all levels of learners and give formal didactic sessions as well to students, residents and fellows. I participate annually in the VIC in both Connections as well as Neuroscience and provide formal didactics during the Medicine Clerkship. In addition, I participate and precept the residents in morning report and provide formal didactic sessions during the Academic Half Day. I have provide formal lectures to other subspecialties residents and fellows both in and outside of the DOM. In the past year I have worked to redesign our Fellow Curriculum and have created a weekly morning didactic session similar to the Academic Half Day in the Medical Resident Curriculum. This has been very well-received by our ID fellows as well as current ID faculty. In addition, I have also

developed a Board Review curriculum designed for the ID fellows which has been popular with attendings and fellows alike. This curriculum is designed to ensure the fellows recognize the clinical presentation, workup and treatment of a wide range of disease entities. Since its inception, we have had a 100% board pass rate for our fellowship program. I have also had the opportunity to lecture regionally on a variety of ID topics including here at UVMMC as well as the Emergency Medicine Conference and the Hospitalist Medicine Conference.

**Summary of Scholarly Activities:**

Although my appointment is in the Clinical Scholar Pathway, I have been actively engaged in human research studies since my appointment as an Assistant Professor in 2008. Most of this work has entailed organizing and heading flavivirus vaccine studies in conjunction with the Vaccine Testing Center for which I have been involved in writing clinical protocols, and am the site PI for all of our current flavivirus studies here at UVM. In this role, I oversee the safety all our volunteers, and am responsible for managing a staff of several clinical coordinators and lab technicians. I also spend time in consultation with our colleagues at the NIH and at Johns Hopkins as it relates to ongoing studies. Since 2009, we have held a contract with the NIH and JHU to study the safety and efficacy of various flavivirus vaccine candidates (Dengue, West Nile Virus, and Zika). As part of this work at UVM, we have worked to develop a safe and effective Controlled Human Challenge Model (CHIM) as a platform to test the safety and efficacy of various vaccine candidates on a smaller scale- before roll out of large Phase III studies. This work has generated the opportunity to publish in several peer-reviewed publications and present our research at both a National and International level. As a result of my vaccine work here at UVM, I have been asked to participate in high level discussions regarding vaccine roll out as a member of both the American Council on Immunization Practices- Flavivirus Working Group here in the US, and as a member of the Candidate Vaccine Advisory Committee (CVAC) Steering Group on Flavivirus Vaccines Indian/US Working group on an international level. Given the safety concerns seen with the current Sanofi dengue vaccine, the decision regarding timing and strategy of vaccine roll out in the US, and abroad is of significant scientific importance at the current time.

In July of this year, we just learned that we have been awarded another 10 year contract with JHU and the NIH to continue our Flavivirus work. This was a huge undertaking on the part of the VTC to recompile for this contract and to receive the award for another 10 years

**PROFESSIONAL SERVICE**

---

DEPARTMENTAL SERVICE

2009-Present	Medicine	Bylaws and Credentials Committee	Member
2009-Present	Medicine	Resident Selection Committee	Member
2015-2017	Medicine	Promotions Committee	Member

2013- Present	Medicine	Faculty Development Committee	Member
2014	Medicine	ID Faculty Recruitment Committee	Member
2016	Medicine	ID Faculty Recruitment Committee	Member
2017-Present	Medicine	Reappointment Sub-committee	Chair
2019-Present	Medicine	DOM RPT Committee	Chair
2014- Present	Infectious Disease	Clinical Competency Committee	Chair
2014- Present	Infectious Disease	Program Evaluation Committee	Chair
2019- Present	Infectious Disease	Expanded Access Program	Founder

COLLEGE SERVICES

2011-2014	Faculty Standards committee	Member
-----------	-----------------------------	--------

MEDICAL CENTER SERVICE

2006-Present	Infectious Disease Practice Committee	Member
2006-Present	Infection Control Committee	Member
2018-2019	Microbiology Search Committee	Member

UNIVERSITY SERVICE

2014-present UVM Institutional Review Board Member  
 2016-2017 Complex Systems Search Committee Member

SOCIETY MEMBERSHIPS

2006-Present Infectious Disease Society of America  
 2007-Present American Society of Tropical Medicine and Hygiene

SERVICE TO PROFESSIONAL PUBLICATIONS

2013-2015 Critical Care Medicine, Reviewer  
 2016-Present American Society of Tropical Medicine and Hygiene, Reviewer

EXTERNAL SERVICE ACTIVITIES

2018- Present American Committee on Immunization Practice (ACIP) Dengue Vaccine Workgroup. CDC  
 2018- Present Candidate Vaccine Advisory Committee (CVAC) Steering Group on preparedness for Flavivirus Vaccines Indian/US Working group Indo-US Vaccine Action Program (Indo-VAP)

**TEACHING**

---

FORMAL SCHEDULED CLASSES

Year	Course Title	Course R E	Hours	Number of Learners	Lear- ner Level
2009-2010	VIC, CMB, Small group “antibiotic resistance:	X	1.0/year	~50	Med
2008- present	VIC, Attacks and Defenses Small Groups	X	3.0/year	~20	Med
2010-Present	VIC, Connections. “Tropical Dermatology”	X	1.0/year	60	Med

2010- Present	Medicine Clerkship, "Urinary Tract Infections"	X		3.0/year	~10	Med
2013- 2018	Global Health Bridge "Emerging Infectious Diseases"	X		2.0/year	~60	Med
2014- Present	VIC, Neuroscience "CNS Infections"	X		2.0/Year	~60	Med

R-required; E-elective; Hours-approx. per semester; G-graduate studies (instruction as per the LCOM Teaching Academy portfolio)

POSTGRADUATE AND OTHER COURSES

2008-Present	Morning Report Medicine Residents	Preceptor, 4-5 times per year
2008- Present	Medicine Resident Academic Half Day	2-3 lectures per year Topics change but include "Soft Tissue Infections, Urinary Tract Infections, Sexually Transmitted Infections, Fever in the Returning Traveler
2011-Present	Pulmonary and Critical Care Fellows Lecture Series	Various topics including: Pneumonia and Fungal Infections
2009-Present	Infectious Disease Fellows Core Lecture Series.	Seven formal lectures per year: $\beta$ -Lactam antibiotics, Urogenital Infections, Protease Inhibitors, Alpha and Flaviviruses, Aspergillus and Mucor, Trematodes and Cestodes, Infectious Disease Mimics
2013-Present	Family Practice Residents.	One Lecture per year on various topics: Endocarditis, Bacteremia
2014	Neurosurgery Residents.	Shunt Infection and Brain Abscess
2018-Present	UVM Summer Health Academy	Yearly panel member on "Women in Medicine"
2019	UVM MMG undergraduate students	Bioterrorism Panel Member in undergraduate "Bioterrorism" class

PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

<b>Dates</b>	<b>Name</b>	<b>Program School</b>	<b>Role</b>	<b>Current Position</b>
2013	Hannah Rickner	UVM	Mentor to undergraduate student interested in Medicine	Ph.D. candidate at University of Massachusetts
2015	Julie MacDougall	UVMMC, Pharmacy Resident	Research Advisor.	Staff Pharmacist at UVMMC

DISSERTATION/THESIS COMMITTEE MEMBERSHIP

POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED

<b>Dates</b>	<b>Name</b>	<b>Fellow</b>	<b>Faculty Role</b>	<b>Current Position</b>
2014	Olha Smolynets	ID Fellow	Research Advisor	Private Practice
2018-9	Daniela DiMarco	ID Fellow	Research Advisor	Academic ID
2011-13	Kensley Nichols	ID Fellow	Fellowship Director	Private Practice
2012-14	Olha Smolynets	ID Fellow	Fellowship Director	Private Practice
2013-15	Vinod Mohan	ID Fellow	Fellowship Director	Academic ID
2014-16	Krystine Spiess	ID Fellow	Fellowship Director	Private Practice
2015-17	Porntip Kiatsimku	ID Fellow	Fellowship Director	Private Practice
2016-18	James Enser	ID Fellow	Fellowship Director	Private Practice
2017-19	Daniela Dimarco	ID Fellow	Fellowship Director	Academic ID
2018-	Prateek Ghatge	ID Fellow, current	Fellowship Director	Current Fellow

RESEARCH AND SCHOLARLY ACTIVITIES

RESEARCH AWARDS AND GRANTS

**Ongoing Research Support**

2009 #CIR 256 Kirkpatrick (PI)

Dengue Vaccine Project at UVM, NIH and Johns Hopkins University

A Phase I Evaluation of the Safety and Immunogenicity of rDEN4Δ30 Lot#109A, a Live Attenuated DEN4 vaccine, in Healthy Flavivirus-naïve Adult Volunteers

Role: Sub Investigator

Direct Costs Year 1: \$999,103 (split between CIR256, CIR253, CIR257, CIR268)

Total Period: \$2,997,309 (split between CIR256, CIR253, CIR257, CIR268)

2010 #CIR253 Kirkpatrick (PI)

Dengue Vaccine Project at UVM, NIH and Johns Hopkins University

A Phase I Evaluation of the Safety and Immunogenicity of rDEN1Δ30, Serotype 1 Vaccine at a single dose of 10<sup>1</sup> PFU in, Healthy Flavivirus-naïve Adult Volunteers.

Role: Sub Investigator

Direct Costs Year 1: \$999,103 (split between CIR256, CIR253, CIR257, CIR268)

Total Period: \$2,997,309 (split between CIR256, CIR253, CIR257, CIR268)

2010 #CIR257 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3Δ30/31-7164,  
A Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3.  
Role: Sub Investigator  
Direct Costs Year 1: \$999,103 (split between CIR256,  
CIR253, CIR257, CIR268)  
Total Period: \$2,997,309 (split between CIR256,  
CIR253, CIR257, CIR268)

2010 #CIR268 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
A Phase I Evaluation of the Safety and Immunogenicity of Five Formulations of TetraVax-  
DV, a Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine in Healthy  
Flavivirus-naïve Adult Subjects  
Role: Sub Investigator  
Direct Costs Year 1: \$999,103 (split between CIR256,  
CIR253, CIR257, CIR268)  
Total Period: \$2,997,309 (split between CIR256,  
CIR253, CIR257, CIR268)

2011 #CIR279 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
A Phase I Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated  
Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-  
naïve Adult Subjects  
Role: Sub Investigator  
Direct Costs Year 1: \$531,384 (split between CIR279 and  
CIR 280)  
Total Period: \$1,062,769 (split between CIR279  
and CIR 280)

2012 #CIR280 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
A Phase I Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated  
Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-  
experienced Adult Subjects  
Role: Sub Investigator  
Direct Costs Year 1: \$531,384 (split between CIR279 and  
CIR 280)  
Total Period: \$1,062,769 (split between CIR279  
and CIR 280)

2013 #CIR283 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
A Phase I Evaluation of the Safety and Immunogenicity of a Booster Dose of TV003  
Administered 12 months After Initial Vaccination with TV003  
Role: **Site Principal Investigator**

Direct Costs Year 1: \$206,518  
Total Period: \$619,556

2013 #CIR287 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
Phase I Placebo-controlled, double blind study Evaluate the ability of a single dose of TV003 to protect against infection with rDEN2Δ30-7169, when administered 6 months following vaccination with TV003

Role: **Site Principal Investigator**  
Direct Costs Year 1: \$189,340  
Total Period \$568,021

2014 #CIR299 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
Phase I Placebo-controlled, double blind study to evaluate the ability of a single dose of TV003 to protect against infection with rDEN2Δ30-7169, when administered 6 months following vaccination with TV005

Role: **Site Principal Investigator**  
Direct Costs Year 1: \$360,948  
Total Period: \$541,423

2015 #CIR300 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
Phase I Placebo- controlled, double blind study to evaluate the ability of a trivalent Dengue Vaccine to protect against infection with rDEN2Δ30-7169, when administered 6 months following vaccination with Trivalent vaccine (UVM PI)

Role: **Site Principal Investigator**  
Direct Costs Year 1: \$263,694  
Total Period: \$395,541

2016 #CIR 304 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
Phase I evaluation of the Safety and Immunogenicity of DEN3Δ30 a live Attenuated Monovalent Dengue Virus Vaccine

Role: **Site Principal Investigator**  
Direct Costs Year 1: \$359,827  
Total Period: \$665,680

2016 #CIR 309 Kirkpatrick(PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University  
Phase I Placebo- controlled, double blind study to evaluate the ability of a trivalent Dengue Vaccine to protect against infection with rDEN3Δ30, when administered 6 months following vaccination with Trivalent vaccine (UVM PI)

Role: **Site Principal Investigator**  
Total Period \$395, 541

2017 #CIR 318 Kirkpatrick (PI)  
Dengue Vaccine Project at UVM, NIH and Johns Hopkins University

A Phase I Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Zika Virus Vaccine in Healthy Flavivirus-experienced Adult Subjects

Role: **Site Principal Investigator**

Total Period \$395,400

2018-2019 #CIR 323 Kirkpatrick (PI)

Dengue Vaccine Project at UVM, NIH and Johns Hopkins University

Phase I Placebo- controlled, double blind study to evaluate the ability of a Tetravalent Dengue Vaccine to protect against infection with rDEN3Δ30 or rDEN2Δ30-7169 , when administered 28 days following vaccination with TV003 LATV (UVM PI)

Role: **Site Principal Investigator**

Total Period \$395, 541

## SCHOLARSHIP

### Original Research

1. Grace CJ, Liberman J, **Pierce K**, Littenberg B. “Usefulness of Blood Cultures for Hospitalized Patients Who are Receiving Antibiotic Therapy.” *Clinical Infectious Diseases* 2001 June 1; 32(11): 1651-5.
2. **Pierce K** and Kirkpatrick BD. Protozoan Infections of the Gastrointestinal Tract. *Current Opinion in Gastroenterology* 2008; 25: 12-17.
3. David R. Tribble, Shahida Baqar, Marya Carmolli, Chad Porter, Catherine J. Larsson, Patricia Guerry, **Kristen Pierce**, Katrin Sadigh, David Rockabrand, Frederic Poly, Cassandra Ventrone, Patrick Daunais, Sandra Dakdouk, Caroline Lyon, Ann Fingar, Christopher Huston, Theron Gilliland Jr., Ericka Jones, Michael Darsley, **Beth D. Kirkpatrick**. *Campylobacter jejuni* strain CG8421: A refined model for the study of campylobacteriosis and evaluation of *Campylobacter* vaccines in human subjects. *Clinical Infectious Diseases* 2009; 49: 1512-9.
4. Lindow JC, Poly F, Tribble DR, Guerry P, Carmolli MP, Baqar S, Porter CK, **Pierce KK**, Darsley MJ, Sadigh KS, Dill AE, Kirkpatrick BD. Caught in the act: *In vivo* development of macrolide resistance to *Campylobacter jejuni* infection. *J Clin Micro* 2010; 48 (8): 3012-5.
5. Ahern J, **Pierce K**. Pharmacokinetics. *Infectious Diseases in Clinical Practice*. 2011;19:16-24
6. Anna P. Durbin, Beth D. Kirkpatrick, **Kristen K. Pierce**, Alexander Schmidt, and Stephen S. Whitehead. The development and clinical evaluation of multiple monovalent DENV vaccines; identification of vaccines for inclusion in a live attenuated tetravalent DENV vaccine. *Vaccine* 2011; 29: 7242-7250 2011.

7. Durbin AP\*, Kirkpatrick BD,\* **Pierce KK**, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. A Single Dose of Any Four Different Live Attenuated Tetravalent Dengue Vaccines is Safe and Immunogenic in Flavivirus-naïve Adults: A Randomized, Double Blind Clinical Trial. *Journal of Infectious Disease*. 2013; 207: 957-6
8. Kirkpatrick BD, Lyon CE, Porter CK, Maue C, Guerry P, **Pierce KK**, Carmolli MP, Riddle MS, Larsson CJ, Hawk D, Dill EA, Poly F, Fimlaid KA, Hoq F, Tribble DR. Lack of Homologous Protection against *Campylobacter jejuni* CG8421 in a Human Challenge Model. *Clinical Infectious Diseases* 2013; 57: 1106-13
9. Lindow JC, Durbin AP, Whitehead SS, **Pierce KK**, Carmolli MP, Kirkpatrick BD. Vaccination of volunteers with low-dose live attenuated dengue viruses leads to distinct immunologic and virologic profiles. *Vaccine* 2013; 31:3347-52
10. Durbin AP\*, Kirkpatrick BD\*, **Pierce KK**, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra E, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. A 12-month interval dosing study in adults indicates that a single dose of the NIAID tetravalent dengue vaccine induces a robust neutralizing antibody response. *Journal of Infectious Diseases*. 2014
11. Kirkpatrick BD, Durbin AP, **Pierce KK**, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchick JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. Robust and Balanced Immune Response to all 4 Dengue Virus Serotypes Following Administration of a Single Dose of Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naïve Adults. *Journal of Infectious Diseases*. 2015 212 (5):702
12. MacDougall J, Ahern J, Civalier M, **Pierce K**, Cohen R. Identification of Risk Factors for Initial Elevated Vancomycin Trough Concentrations. *Journal of Pharmacy Technology* 2016;32:289-33
13. Durbin AP, Kirkpatrick BD, **Pierce KK**, Whitehead SS A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. *J Infect Dis*. 2016; 214: 832-5
14. Kirkpatrick BD, Whitehead SS, **Pierce KK**, Tibery CM, Grier, PL, Hynes NA, Larsson, CJ, Sabundayo BP, Talaat KR, Jania A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP. The Live Attenuated Dengue Vaccine TV003 elicits Complete Protection Against Dengue in a Human Challenge Model. *Science and Translational Medicine*. 2016;8
15. **Pierce K**, Whitehead S, Kirkpatrick B, Grier P, Jarvis A, Kenney H, Carmolli M, Reynolds C , Tibery C, Lovchic J, Janiak A, Luke C, Durbin A, Pletnev A. The Live Attenuated Chimeric Virus rWN/DEN4Δ30 is Well-Tolerated and Immunogenic in Healthy Older Adult Volunteers. *Journal of Infectious Diseases* 2017; 215: 52-55

16. Whitehead SS, Durbin AP, **Pierce KK**, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, Lovchik JM, Larsson CJ, Doty EA, Dickson DM, Luke CJ, Subbarao K, Diehl SA, Kirkpatrick BD. In a Randomized Trial, the Live Attenuated Tetravalent Dengue Vaccine TV003 is Well-Tolerated and Highly Immunogenic in Subjects with Flavivirus Exposure Prior to Vaccination. *PLoS Negl Trop Dis*. 2017 May 8;11(5)
17. Nivarthi U, Huy A, Delacruz M, Swantrom J, Bhumi P, Durbin A, Whitehead S, **Pierce K**, Kirkpatrick B, Baric R, Nguyen N, Emerling D, Silva A, Diehl S. Dengue Virus Type 2 Human Infection Model: Longitudinal Analysis of Acute and Convalescent Stage B cell Responses in a Human Primary Dengue Serotype 2 Infection Model. *EBioMedicine*. 2019 Mar;41:465-478
18. Campbell RA, Scwertz H, Hottz ED, Rowley JW, Manne BK, Washington AV, Hunter-Mellado R, Tolley ND, Christensen M, Eustes AS, Montenont E, Bhatlekar S, Ventrone CH, Kirkpatrick BD, **Pierce KK**, Whitehead SS, Diehl SA, Bray PF, Zimmerman GA, Kosaka Y, Bozza PT, Weyrich AS, Rondina MT. Human Megakaryocytes Possess Intrinsic Antiviral Immunity Through Regulated Induction of IFITM3. *Blood*. 2019 May 9;133 (19) 2013-2026
19. **Pierce K**, Whitehead S, Diehl S, Carmolli M, Naro G, Kirkpatrick B, Durbin A. Evaluation of a New Dengue 3 Controlled Human Challenge Model For Use in Evaluation of Candidate Dengue Vaccines. 2019 In revision, with plans to submit to JID
20. Graham N, Eisenhauer P, Diehl SA, Pierce KK, Whitehead SS, Durbin AP, Kirkpatrick BD, Sette A, Weiskopf D, Boyson JE, Botten JW. Rapid Induction and Maintenance of Virus-Specific CD8+TEMRA and CD4+TEM Cells Correlates with Complete Protection in a Human Model of Tetravalent Dengue Virus Vaccination and Challenge. Submitted to *Frontiers in Immunology* December 2019
21. Nivarthi, UK, Swantstrom J, Delacruz M, Patel B, Durbin A, Whitehead SS, Kirkpatrick, BD, **Pierce KP**, Diehl SA, Katzelnick L, Baric R, deSilva, AM. A Tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. Submitted to *Science Translational Medicine* January 2020

#### Books and Chapters

1. **Pierce K**, Huston CD. Pathogenesis: Protozoan, Intestinal. In: Encyclopedia of Microbiology. Schaechter M, editor. San Diego, CA: Elsevier, Inc. 2008.
2. **Pierce K**, Huston CD. Protozoan, Intestinal. In: *Eukaryotic Microbiology*. Schaechter M, editor. San Diego, CA: Elsevier, Inc. 2012. p. 323-333.
3. **Pierce K**. “Immunocompromised Host”. In: Critical Care Secrets 5<sup>th</sup> Edition. Parsons, P, and Wiener-Kronish J, editors. St Louis, Missouri: Elsevier, Inc. 2013. P. 277-292

4. **Pierce K.** “Immunocompromised Host”. In: Critical Care Secrets 6<sup>th</sup> Edition. Parsons, P, and Stapleton, R. editors. St Louis, Missouri: Elsevier, Inc. 2018 P. 282-294

## Abstracts

1. **Pierce, K,** Teixeira, J, Huston, C Validation of Glycolytic enzymes as Drug Targets for *Cryptosporidium*. Abstract. Accepted to ICAAC/IDSA 2008. #11-08-A-2635
2. Lyon CE, Carmolli M, Lindow J, Harro C, Sheldon E, Larsson CJ, Ventrone C, Sadigh K, Ventrone CH, **Pierce KK,** Fingar A, Dill E. Kirkpatrick BD. The novel, single oral dose typhoid vaccine M01ZH09 is safe and immunogenic at doses up to  $1.7 \times 10^{10}$  Colony-forming units. Vaccines for Enteric Diseases Conference, Malaga, Spain. 2009. *Oral Presentation*
3. **Pierce K,** Kirkpatrick, B Durbin, A Lindow, J Carmolli, M Shaffer, D Colgate, E Larsson, C Wanionek, K Andrada, A Stephen, S Evaluation of Low Dose Monovalent Dengue Vaccines in Human Volunteers. ASTMH 2011, Philadelphia 2011
4. Kirkpatrick BD, Durbin AP, **Pierce KP,** Lindow J, Elwood D, Wanionek K, Andrada A, Carmolli M, Whitehead SS. Evaluation of the safety and immunogenicity of TETRAVAX-DV, a live attenuated tetravalent dengue vaccine. Dengue Vaccine Initiative, Washington DC 2011.
5. **Pierce KK** and Kirkpatrick BD, Durbin AP, Lindow JC, Carmolli MP, Shaffer D, Colgate R, Larsson CJ, Wanionek K, Walsh MC, Andrada A, Whitehead SS. Evaluation of low dose monovalent dengue vaccines in human volunteers. American Society Tropical Medicine Hygiene, Philadelphia, December 2011.
6. Stephen Whitehead, Anna Durbin, Beth Kirkpatrick, **Kristen Pierce,** Marya Carmolli, Cathy Larsson, Dan Elwood, Cecilia Tibery, Kimberli Wanionek, Janece Lovchik, Catherine Luke. A single dose of the NIH live attenuated tetravalent dengue vaccine is safe, immunogenic, and capable of neutralizing subsequent vaccine challenge. Third Pan-American Dengue Research Network Meeting, Cartagena, Colombia. September 2012.
7. Durbin A, Kirkpatrick BD, **Pierce KK,** Whitehead S. The Safety and Immunogenicity of the Live-Attenuated Tetravalent Dengue Candidate Vaccine TV003 in Flavivirus-experienced Subjects. American Society of Tropical Medicine Annual Meeting. November 2013
8. Smolynets, Olha. **Pierce, Kristen.** “The First Case of EEE in Vermont” Presented at: Vermont Infectious Disease Conference. October 18-19, 2013. Burlington, VT.
9. Olha Smolynets, DO, **Kristen Pierce, MD,** Laura Greene, MD, Sean Diehl, PhD, Douglas Taatjes, PhD, Anna Durbin, MD, Stephen Whitehead, PhD and Beth Kirkpatrick, MD Dermatologic Manifestations in Live Attenuated Dengue Vaccines: A Skin Biopsy study. IDSA Annual Meeting. Philadelphia, PA October 2014.

10. **Pierce K**, Whitehead S, Kirkpatrick B, Carmolli M, Tibery C, Eby Y, Larsson C, Grier P, Ostrowski E, Durbin A. “A Phase I Evaluation of the Safety and Immunogenicity of the rDEN3Δ30 as a Dengue 3 Human Challenge Strain. American Society of Tropical Medicine and Hygiene. November 13-17, 2016. Atlanta, GA
11. Tu H, Nivarthi U, Emerling D, Widman D, Baric R, **Pierce K**, Whitehead S, Kirkpatrick B, Durbin A, de Silva A, Diehl S. “ Longitudinal Analysis of B cell Response to Infection with a Dengue-2 Challenge Virus.” American Society of Tropical Medicine and Hygiene. November 13-17, 2016. Atlanta, GA
12. Collier BA, Durbin A, Kirkpatrick B, **Pierce K**, Grier P, Sabundayo B, Larsson C, He Helen, Sausser M, Russell A, Martin J, Sachs J, Lee A, Villarreal S, Wang L, Coren A, Traina S, Whitehead S. “A Phase I Clinical Trial Evaluating the Impact of Tetravalent Recombinant Subunit Dengue Vaccine Boost Administered to Subjects Who Have Previously Been Vaccinated with a Live- Attenuated Tetravalent Dengue Vaccine: American Society of Tropical Medicine and Hygiene. November 13-17, 2016 Atlanta, GA
13. Durbin A, Kirkpatrick B, Tibery C, Grier P, **Pierce K**, He H, Eby Y, Carmolli M, Ventrone C, Diehl S, Whitehead S. “A Single dose of TV005 Elicits Complete Protection Against Challenge with Heterotypic DENV2Δ30”. American Society of Tropical Medicine and Hygiene. November 13-17, 2016. Atlanta, GA.
14. Rigby B, **Pierce K**. Babesiosis: Relapse or Reinfection? American College of Physicians Vermont Chapter Annual Meeting. October 2018. Stowe, VT
15. Dimarco, D, Kennedy, A, Read J, **Pierce K**.”Pre-exposure Prophylaxis (PrEP) for HIV in Vermont: as Assessment of Prescribing in a Uniquely Rural State.” Accepted for presentation at IDSA Annual Meeting, October 2019. Washington, DC

## INVITED PRESENTATIONS

### **Regional**

2012	OB/GYN Grand Rounds:“Sexually Transmitted Infections”	Burlington, VT
2013	VT AHEC Network “Eastern Equine Encephalitis and West NileVirus”	White River Junction, VT
2013	Vermont Infectious Disease Conference “Zoonotic and Vectorborne Disease	Burlington, VT
2013	Invited Interviewee on WPTZ “West Nile Virus”	Burlington, VT
2013	Invited Interviewee on WCAX “West Nile Virus”	Burlington, VT
2013	Hospitalist Medicine Conference “Lyme Disease”	Stowe, VT

2014	Emergency Medicine Update Course “International Travel and Illness”	Stowe, VT
2014	Hospitalist Medicine Conference “Hospital and Ventilator Associated Pneumonia”	Stowe, VT
2014	Annual Meeting of The American College of Physicians, VT chapter “Tick Borne Infections”	Stowe, VT
2014	Vermont Immunization and Infectious Disease Conference. “Hepatitis C”	Stowe, VT
2014	Urology Grand Rounds:“Urinary Tract Infections”	Burlington VT
2015	Pharmacy Grand Rounds: “Malaria”	Burlington, VT
2015	Emergency Medicine Update Course “Commonly Asked ID Curbsides”	Stowe, VT
2016	Infection Prevention Advocates Meeting “Hepatitis C”	Burlington, VT
2016	Emergency Medicine Update Course “Infectious Disease Updates”	Stowe, VT
2016	Annual Meeting of The American College of Physicians, VT chapter “Vector Borne Diseases”	Burlington, VT
2016	Community Medical School, UVM “Zika and Dengue”	Burlington, VT
2017	Emergency Medicine Update Course “Infectious Disease Emergencies”	Stowe, VT
2017	Hospitalist Medicine Conference “Endocarditis”	Stowe, VT
2017	Vermont Department of Health Grand Rounds “Dengue and West Nile Virus Vaccine Development”	Burlington, VT
2018	Emergency Medicine Update Course “Questions about Tick-related Disease”	Stowe, VT
2018	Hospital Medicine Conference “Tick-Borne Disease”	Stowe, VT
	Interview of WCAX, “Zika Vaccine”	

2018		Burlington, VT
2019	“Top 10 Pharyngitis Syndromes” Emergency Medicine Conference	Stowe, VT
2019	“Management of Diabetic Foot Infections” Hospitalist Medicine Conference	Stowe, VT
<b>National</b>		
2012	Avancees Vaccinales. 15 <sup>th</sup> Annual Conference on Vaccine Research. “Dengue Disease”	Baltimore, MD
2015	MERCK SIE for Dengue Collaborators “Skin Biopsy Findings in Dengue Vaccines”	Philadelphia, PA
2016	American Society of Tropical Medicine and Hygiene. Annual Meeting “West Nile Virus Vaccine in Older Adults”	Atlanta, GA
<b>International</b>		
2009	Second Pan-American Dengue Research Network Meeting. “Clinical Evaluation Of a Live- Attenuated Dengue Vaccine”	Cancun, Mexico
2019	“NIH Candidate Dengue Vaccines” Candidate Vaccine Advisory Committee Steering Group (CVAC) on Epidemiologic Preparedness for Flavivirus Vaccine	New Delhi, India
2019	“Future of the NIH Live Attenuated Tetravalent Vaccine” Working Group for Dengue Vaccines, Iccdr, b in Dhaka, Bangladesh	Dhaka, Bangladesh